Retatrutide Peptide 10 mg

Retatrutide (LY‑3437943) is an investigational peptide that simultaneously activates the GLP‑1, glucose‑dependent insulinotropic polypeptide (GIP) and glucagon receptors. Early clinical trials for obesity and type 2 diabetes show once‑weekly retatrutide injections may reduce body weight by up to 24 % over 48 weeks:contentReference[oaicite:41]{index=41}. However, this compound is not yet approved for therapeutic use; grey‑market sales are illegal and pose significant safety risks:contentReference[oaicite:42]{index=42}.

Disclaimer: For laboratory research only; not for human use.